Impact of Catecholamines to Insulin-Glucose Homeostasis in IUGR Fetuses

儿茶酚胺对 IUGR 胎儿胰岛素-葡萄糖稳态的影响

基本信息

  • 批准号:
    8245809
  • 负责人:
  • 金额:
    $ 25.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-04-15 至 2014-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Impact of Catecholamines to Insulin-Glucose Homeostasis in IUGR Fetuses Endocrine factors such as catecholamines promote fetal survival during intrauterine growth restriction (IUGR) by sparing glucose for critical functions. A primary fetal response to IUGR is to suppress 2-cell function and lower the anabolic hormone, insulin. The goal of this research project is to understand the mechanisms by which chronic catecholamine stimulation (coupled with hypoxia and hypoglycemia) modulates insulin secretion in fetal sheep with placental insufficiency, a model system that shares many similarities to human IUGR fetuses with placental insufficiency. Our data indicates that chronic exposure to high catecholamine concentrations leads to 2-cell desensitization by augmenting their insulin secretion responsiveness. In postnatal life, when catecholamine suppression is no long present, a hyper-responsiveness to glucose is apparent, and potentially results from the 2- cells desensitization adaptation to fetal catecholamines. We will test the hypothesis that chronic exposure to elevated catecholamine concentrations lowers insulin secretion in the IUGR fetus, but also leads to adrenergic desensitization in 2-cells that enhances glucose stimulated insulin secretion after suppressive conditions are alleviated in the neonate with the following specific aims. First, we will determine the onset and consequences of chronic catecholamine suppression to glucose stimulated insulin secretion (GSIS) in sheep fetuses with placental insufficiency-induced IUGR. Second, we will determine if chronic catecholamine desensitization for the fetal 2-cells occurs in the proximal adrenergic receptor signaling pathway, insulin stimulus secretion coupling pathway, or both. Finally, in pre-ruminant lambs we will determine whether residual compensatory actions from catecholamine suppression in fetal life leads to the overcorrection in insulin secretion responsiveness as a result of proximal adrenergic signaling or increased insulin stimulus secretion coupling. It is likely that such explanations will increase capacity for promoting 2-cell function in human IUGR infants. These concepts and this type of investigation have not been done in the fetus, but represent reasonable points of regulation that based on the literature and general understanding of catecholamine action should play significant roles. Therefore, these studies will provide new insight into the requirements for clinical intervention to ameliorate pancreatic insufficiency in IUGR fetuses and neonates with the goal of reducing fetal and neonatal morbidity and mortality, and potentially lower the incidence of adult onset diseases that have been correlated with low birth weight. PUBLIC HEALTH RELEVANCE: Fetal growth restriction continues to contribute to major medical problems for the fetus, newborn infant, and even the adult, which is highlighted by recent epidemiological studies in Diabetics. Patients with Type 2 Diabetes are reaching epidemic proportions in the United States and consume one of every eight dollars spent for health care. As much as one fifth of this epidemic arises from a nutritional discordance between prenatal and postnatal life that results in impaired glucose homeostasis. Therefore, we plan to determine how a key stress response alters the developmental program in the fetal 2-cells to impair glucose homeostasis and lead to adulthood pathologies, such as Type 2 Diabetes Mellitus.
描述(由申请人提供):儿茶酚胺对IUGR胎儿胰岛素-葡萄糖稳态的影响儿茶酚胺等内分泌因子通过为关键功能节省葡萄糖来促进胎儿在宫内生长受限(IUGR)期间的存活。胎儿对IUGR的主要反应是抑制2-细胞功能,降低合成代谢激素胰岛素。这项研究的目的是了解慢性儿茶酚胺刺激(加上缺氧和低血糖)调节胎盘功能不全胎羊胰岛素分泌的机制,这是一个与人类IUGR胎盘功能不全胎儿有许多相似之处的模型系统。我们的数据表明,长期暴露在高儿茶酚胺浓度下,会通过增强胰岛素分泌反应而导致2-细胞脱敏。在出生后的生活中,当儿茶酚胺抑制不再存在时,对葡萄糖的高反应性是明显的,潜在的原因是2-细胞对胎儿儿茶酚胺的脱敏适应。我们将验证这一假设,即长期暴露于高儿茶酚胺浓度会降低IUGR胎儿的胰岛素分泌,但也会导致2-细胞的肾上腺素能脱敏,在新生儿的抑制条件得到缓解后,肾上腺素能脱敏增强葡萄糖刺激的胰岛素分泌。首先,我们将确定慢性儿茶酚胺抑制葡萄糖刺激的胰岛素分泌(GSIS)在胎盘功能不全诱发IUGR的绵羊胎儿中的发生和后果。其次,我们将确定儿茶酚胺对胎儿2-细胞的慢性脱敏是发生在近端肾上腺素能受体信号通路中,还是发生在胰岛素刺激分泌偶联通路中,或者两者都发生。最后,在反胃前期的羔羊中,我们将确定胎儿生命中儿茶酚胺抑制的残余代偿作用是否会导致胰岛素分泌反应性的过度纠正,这是由于近端肾上腺素能信号或胰岛素刺激分泌偶联增加的结果。这样的解释很可能会增加促进人类IUGR婴儿2-细胞功能的能力。这些概念和这种类型的研究尚未在胎儿中进行,但根据文献和对儿茶酚胺作用的一般理解,这些概念代表了合理的调节点,应该发挥重要作用。因此,这些研究将为临床干预改善IUGR胎儿和新生儿胰腺功能不全的需求提供新的见解,以降低胎儿和新生儿的发病率和死亡率,并潜在地降低与低出生体重相关的成人发病疾病的发生率。与公共卫生相关:胎儿生长受限继续导致胎儿、新生儿,甚至成人的重大医疗问题,这一点在最近的糖尿病流行病学研究中得到了强调。在美国,2型糖尿病患者正在达到流行的程度,他们在医疗保健上的支出占到了每八美元中的一美元。高达五分之一的疫情是由出生前和出生后生活中的营养失调引起的,导致血糖稳态受损。因此,我们计划确定关键的应激反应如何改变胎儿2-细胞的发育程序,从而破坏葡萄糖稳态,并导致成年后的病理,如2型糖尿病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SEAN W LIMESAND其他文献

SEAN W LIMESAND的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SEAN W LIMESAND', 18)}}的其他基金

Prevention of Placental Insufficiency Improves Beta-Cells Function
预防胎盘功能不全可改善 β 细胞功能
  • 批准号:
    10443326
  • 财政年份:
    2022
  • 资助金额:
    $ 25.79万
  • 项目类别:
Prevention of Placental Insufficiency Improves Beta-Cells Function
预防胎盘功能不全可改善 β 细胞功能
  • 批准号:
    10578797
  • 财政年份:
    2022
  • 资助金额:
    $ 25.79万
  • 项目类别:
Prevention of fetal adrenergic signaling improves metabolic dysfunction in IUGR
预防胎儿肾上腺素能信号传导可改善 IUGR 的代谢功能障碍
  • 批准号:
    9013470
  • 财政年份:
    2009
  • 资助金额:
    $ 25.79万
  • 项目类别:
Impact of Catecholamines to Insulin-Glucose Homeostasis in IUGR Fetuses
儿茶酚胺对 IUGR 胎儿胰岛素-葡萄糖稳态的影响
  • 批准号:
    7802160
  • 财政年份:
    2009
  • 资助金额:
    $ 25.79万
  • 项目类别:
Impact of Catecholamines to Insulin-Glucose Homeostasis in IUGR Fetuses
儿茶酚胺对 IUGR 胎儿胰岛素-葡萄糖稳态的影响
  • 批准号:
    8049119
  • 财政年份:
    2009
  • 资助金额:
    $ 25.79万
  • 项目类别:
Impact of Catecholamines to Insulin-Glucose Homeostasis in IUGR Fetuses
儿茶酚胺对 IUGR 胎儿胰岛素-葡萄糖稳态的影响
  • 批准号:
    8443846
  • 财政年份:
    2009
  • 资助金额:
    $ 25.79万
  • 项目类别:
Prevention of fetal adrenergic signaling improves metabolic dysfunction in IUGR
预防胎儿肾上腺素能信号传导可改善 IUGR 的代谢功能障碍
  • 批准号:
    8886932
  • 财政年份:
    2009
  • 资助金额:
    $ 25.79万
  • 项目类别:
Impact of Catecholamines to Insulin-Glucose Homeostasis in IUGR Fetuses
儿茶酚胺对 IUGR 胎儿胰岛素-葡萄糖稳态的影响
  • 批准号:
    7652919
  • 财政年份:
    2009
  • 资助金额:
    $ 25.79万
  • 项目类别:
Aberrant Ovine Pancreatic Development in IUGR Fetuses
IUGR 胎儿的羊胰腺发育异常
  • 批准号:
    6949685
  • 财政年份:
    2004
  • 资助金额:
    $ 25.79万
  • 项目类别:
Aberrant Ovine Pancreatic Development in IUGR Fetuses
IUGR 胎儿的羊胰腺发育异常
  • 批准号:
    7068396
  • 财政年份:
    2004
  • 资助金额:
    $ 25.79万
  • 项目类别:

相似海外基金

Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8358448
  • 财政年份:
    2012
  • 资助金额:
    $ 25.79万
  • 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8517552
  • 财政年份:
    2012
  • 资助金额:
    $ 25.79万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7952159
  • 财政年份:
    2009
  • 资助金额:
    $ 25.79万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7952152
  • 财政年份:
    2009
  • 资助金额:
    $ 25.79万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7719194
  • 财政年份:
    2008
  • 资助金额:
    $ 25.79万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7605416
  • 财政年份:
    2007
  • 资助金额:
    $ 25.79万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7605425
  • 财政年份:
    2007
  • 资助金额:
    $ 25.79万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7378753
  • 财政年份:
    2006
  • 资助金额:
    $ 25.79万
  • 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
  • 批准号:
    6825160
  • 财政年份:
    2004
  • 资助金额:
    $ 25.79万
  • 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
  • 批准号:
    2702283
  • 财政年份:
    1997
  • 资助金额:
    $ 25.79万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了